OnCo
technologiesTechnologyEstablished

Generic oncology drug supply and shortage mitigation

Keeping cheap, essential chemotherapy drugs like cisplatin available; shortages in 2023 forced rationing in US hospitals.

Sterile injectable generics (platinums, 5-FU, methotrexate) have thin margins and few manufacturers; the 2023 cisplatin/carboplatin shortage followed an FDA import alert on Intas. Responses: temporary imports (Qilu), Civica Rx and Phlow non-profit manufacturing, the White House/HHS supply-chain resilience programme, and FDA's Drug Shortage Task Force. Europe's Critical Medicines Act (2025) targets similar risks.

Generic schematic · not to scale · placeholder for the chemotherapy front
Chromosomes at spindle · Drug blocks division / damages DNA

How it works

Redundant qualified sources, strategic reserves, and pricing floors to keep low-margin essential drugs in production.

Strengths
  • Policy attention since 2023
Limitations
  • Economics still unfavourable
  • Quality problems at concentrated sites recur

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Generic oncology drug supply and shortage mitigation" OR ABSTRACT:"Generic oncology drug supply and shortage mitigation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Generic oncology drug supply and shortage mitigation, not a curated reading list.

Connected

7top